Abstract: An aqueous composition with a higher-than-neutral pH includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. This composition, as well as an acidic counterpart and solid materials, can be used in a variety of applications such as wound care, oral care, medical equipment reprocessing, healthcare acquired infection and implant treatment.

Abstract: This invention relates to an antimicrobial composition, especially one which provides synergistic anti-dandruff efficacy. This is achieved through a judicious combination of anti-dandruff agent zinc pyrithione and an alcoholic compound of specific types. These compositions can be delivered through very many different types of personal care products e.g. shampoo or conditioner.

Abstract: This invention relates to an antimicrobial composition, especially one which provides synergistic anti-dandruff efficacy. This is achieved through a judicious combination of anti-dandruff agent zinc pyrithione and a piperazine compound of specific type. These compositions can be delivered through very many different types of personal care products e.g. shampoo or conditioner.

Abstract: The invention relates to a liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and a xanthine compound, and also to a cosmetic composition containing such a mixture. Use for caring for, making up and cleansing keratin materials.

Abstract: The instant disclosure relates to cosmetic compositions that when applied to skin instantaneously and dramatically improve the appearance of the skin. The compositions include at least one water-dispersible primary film forming polymer having a Young's modulus of 0.1 to 50 MPa, an elongation at break >50%, and a glass transition temperature of <0° C.; optionally, at least one secondary, non-polyurethane film forming polymer having a glass transition temperature of <25° C.; optionally, at least one pressure sensitive adhesive polymer; soft focus powders; and water. Methods of using the cosmetic compositions, for example, methods for improving the appearance, are also disclosed.

Abstract: The present disclosure relates to hair conditioning compositions and to methods for conditioning hair using the hair conditioning compositions. The hair conditioning compositions typically include: at least one amino functional silicone; at least one nonionic silicone polymer; at least one ampholytic polymer comprising a repetition of: (i) one or more units obtained from a monomer of (meth)acrylamide type, (ii) one or more units obtained from a monomer of (meth)acrylamidoalkyltrialkylammonium type, and (iii) one or more units obtained from an acidic monomer of (meth)acrylic acid type; and water. The hair conditioning compositions are unique because they are particularly useful for conditioning hair before the hair is washed with a shampoo. Thus, the present disclosure also relates to methods of conditioning hair and in particular in a routine for conditioning hair where the hair is first treated with a hair conditioning composition followed by treatment with a shampoo.

Abstract: Hair treatment agents including: at least one fatty alcohol; at least one cationic surfactant; at least one silicone; and 10-undecenoic acid and/or salts thereof.

Abstract: A cosmetic containing an organosiloxane graft polyvinyl alcohol polymer having a structural unit shown by the general formula (1) and a structural unit shown by the general formula (3). The organosiloxane graft polyvinyl alcohol polymer has a number average molecular weight (Mn) of 5,000 to 500,000 as measured by GPC. There can be provided a cosmetic which has favorable feeling on use and oil resistance, and which is excellent in cosmetic durability improvement. where M1 and M2 each represent a hydrogen atom, an acetyl group, or a siloxane group shown by the general formula (2), provided that at least one of M1 and M2 is a siloxane group shown by the general formula (2); and A represents a single bond or a linking group, where M3 represents a hydrogen atom, an acetyl group, or a siloxane group shown by the formula (2).

Abstract: A composition for topical application containing at least one combination of (a) polyphenols selected from proanthocyanidin monomers and oligomers (OPC), hydroxystilbenes, flavonoid monomers and oligomers, and derivatives and mixtures thereof, (b) a spruce extract having at least one lignan selected from: hydroxymatairesinol, secoisolariciresinol, conidendrin, lariciresinol and liovile. It also relates to the cosmetic use of such a combination for combating the signs of ageing of the skin or hair and nails or the effects of pollution, and a cosmetic treatment method using said combination.

Abstract: Disclosed is an alcoholic extract of aerial parts of Anthyllis vulneraria, method for obtaining same, a cosmetic or dermatological composition containing same, as well as the cosmetic and dermatological uses thereof, in particular in depigmenting the skin.

Abstract: The present invention is related to a cosmetic method for promoting lipolysis, slimming, draining, smooth skin surface, reducing the volume of localized fat deposits, the method including applying a topical composition comprising a Nelumbo nucifera (Lotus) Extract.

Abstract: The present invention provides a process for obtaining an extract from peach flower extract (Primus persica L.) for skin cosmetic use, a peach flower extract obtainable by the process and a cosmetic composition comprising the said extract. The invention further provides a method for modulating the SIRT2 expression, a method of treatment designed to reduce and/or correct the signs of aging and photo-aging of the skin and keratinous appendages, and to protect the skin against aggressions due to ultraviolet radiation.

Abstract: A skin care composition for stimulating selective catabolysis in cells of keratin surfaces comprising at least one autophagy activator and at least one proteasome activator, and a method for improving selective catabolysis in cells of keratin surfaces by treating with the composition.

Abstract: The present invention provides devices and methods for delivering a population of cells or a therapeutic agent to a subject in need thereof.

Abstract: An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.

Abstract: A simple, self-propelling particle system is disclosed that can deliver a cargo through flowing aqueous solutions. This disclosure provides a non-aqueous composition comprising: (i) particles formed of a carbonate salt and having an average diameter of about 100 ?m or less; and (ii) an acid in solid form. The particles may be associated with a cargo molecule or particle. In mouse models of severe hemorrhage, the propelled particles are able to deliver a procoagulant enzyme and halt bleeding.

Abstract: The present invention is a new controlled drug system that can be used for targeting non-invasive neuromodulation enabled by focused ultrasound gated release of one or more small molecule neuromodulatory agents.

Abstract: This disclosure is directed to the topical/transdermal administration of the phytochemical, Withaferin A (WFA), for its wide range of pharmacological applications to include its anti-cancer, anti-obesity, anti-diabetic, anabolic effect on osteoporotic bone and its many other proteasomal inhibitory effects.

Abstract: The present invention relates to a composition comprising glycocholic acid or taurocholic acid and phosphatidylcholine at a particular mixing ratio for reducing localized fat without side effects such as a pain, edema, necrosis of muscle cells, fibroblasts and vascular endothelial cells other than adipocytes, anesthesia of administration sites, extensive swelling, erythema, induration, paresthesia, nodule, pruritus, burning sensation, nerve injury, and dysphagia, and a method for preparing the same. The inventor has found that the effect of PPC injectable composition on fat reduction may be reduced or enhanced during its subcutaneous administration, depending on the types of solubilizing agents, especially the types of bile acids, which are combined so as to prepare a safe and stable PPC injection using insoluble PPC.

Abstract: Drug delivery devices and methods of administering drugs to patients are provided. A device (50) includes a reservoir (60) containing a drug (58). The reservoir (60) is defined by a wall (64) having a water-permeable portion, such that the water-permeable portion permits water to enter the device (50) and contact the drug (58). A restraining plug (56) closes off an opening of the device (50) such that transient microchannels (62) form between an elastic portion (54) of the device (50) and the restraining plug (56), upon the generation of a sufficient pressure within the reservoir (60), to release the drug (58) from the device (50). Methods of treating patients for neurogenic detrusor overactivity resulting from a spinal cord injury and/or for idiopathic overactive bladder and urinary incontinence are also described.

Abstract: Systems and methods for removal of human cerumen are provided. A composition for removal of cerumen includes at least one cerumenolytically acceptable active agent and an otologically acceptable vehicle. The cerumenolytically acceptable active agent may be an alpha-hydroxy acid (AHA). Exemplary AHA may include, but are not limited to, glycolic acid, tartronic acid, lactic acid, malic acid and any derivative or mixture thereof. The otologically acceptable vehicle may be sodium or potassium salts of bicarbonate aqueous buffer. Yet further, the otologically acceptable vehicle may contain sodium docusate. Cerumen may be removed and/or a cerumen impaction may be treated by administering to a patient in need thereof a composition comprising an AHA and an otologically acceptable vehicle.

Abstract: A composition for oral administration of a bioactive agent to aquatic or terrestrial species includes particles each of which includes a bioactive agent dispersed in oil droplets, the oil droplets being dispersed in a matrix including an enteric coating polymer, wherein the particles each further include a mucoadhesive polymer. Methods of making and using the composition are also provided.

Abstract: A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.

Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Abstract: Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.

Abstract: A packaged treatment composition comprising a polymerisable and/or curable composition comprising (1) a packaged first flowable component comprising a source of hydrogen peroxide and (2) a separately packaged second flowable component; the composition comprising a polymerisable monomer or oligomer, a polymer and/or a curing agent, wherein the composition comprises a photoinitiator and wherein the first flowable component is substantially free of photoinitiator, the composition capable of forming a solid composition by UV-initiated polymerisation and/or curing following mixing of the first and second flowable components.

Abstract: The object of the invention is to elevate the stability of an aqueous formulation comprising ALAs and an iron compound. The present invention provides an aqueous formulation comprising ALAs and an iron compound, characterized in that it further comprises 0.2-30% by weight of salts, said salts are sodium salts or potassium salts, and the pH of said aqueous formulation is 2-8.

Abstract: An improved method for the manufacture of an oil-in water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) micro fluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration, of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.

Abstract: The present disclosure provides a pharmaceutically acceptable, stable, and optically clear oil-in-water nanoemulsions (intensity-averaged diameter<100 nm) with an oil phase comprising >10% w/v of long chain triglyceride, total surfactant and cosurfactant concentration less than that of oil phase and without the use of alcohol as cosolvent in the aqueous phase. The nanoemulsions of this disclosure have extremely favorable particle size distribution, optical clarity, and product stability against Ostwald ripening with high levels of oil concentrations. Poorly water soluble, therapeutically active agents and others can be incorporated in the nanoemulsion systems to improve their solubility/stability in aqueous medium or to enhance their delivery for use in pharmaceutical, food, cosmetic, and other applications by oral, intravenous, subcutaneous, intra muscular, inhalation, nasal, topical, ocular, and transdermal routes.

Abstract: The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.

Abstract: The invention discloses a method for the formation of liposomes by using high shear mixing of aqueous solution of lipid powder; the lipid powder can be produced by any known technique. Components of the liposomes include but are not limited to cationic lipids, immunostimulators/immunopotentiators and macromolecules as components for the liposome formation. The disclosed method describes the formulation of stable liposomes solitary or complexing high concentrations of macromolecules such as proteins, DNA and RNA having opposite charge of the liposomes by high shear mixing where aggregation is avoided due to the formulation method.

Abstract: The present invention provides methods and systems for producing liposomes by filtration. The methods include passing a heated lipid suspension through a filter assembly comprising two or more filters connected in series, wherein an orifice is disposed between adjacent filters. The methods and systems can produce liposomes having an average diameter that is less than half the diameter of the filter pores. Further, the methods and systems can produce liposomes with <100 nm average diameter, even when the liposomes comprise at least 30% sterol.

Abstract: Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.

Abstract: A solid composition with rapid ingestion and facilitated swallowing, in the form of non-agglomerated solid particles, said composition comprising the following two different types of particle: Pa particles, with very low solubility in saliva and comprising at least one active ingredient, and Ps particles, rapidly soluble in saliva, characterised by an apparent density equal to or greater than approximately 0.6 g.cm?3, advantageously equal to or greater than approximately 0.7 g.cm?3, and preferably between 0.7 and 1.5 g.cm?3 inclusive.

Abstract: Sustained release formulations of opioid antagonists containing both free and encapsulated opioid antagonist are described herein.

Abstract: The present invention provides an excipient which can form a tablet, which is capable of rapidly disintegrating in water or in the body, from a functional powder such as a powdered cleaning agent or a powdered medicine. The excipient of the present invention is an excipient for tableting a powder and characterized by containing: starch, crystalline cellulose, and one or more hardening agents selected from the group consisting of maltitol, isomalt, maltose, and lactose. Thus, the excipient of the present invention facilitates tableting of a powder by a conventional procedure. The resulting tablet has excellent solubility in water, and dissolves rapidly after the tablet is placed in water. In addition, the resulting tablet has excellent hardness and can generally retain a predetermined shape with little damage, such as chipping, caused by external forces applied during storage or transportation.

Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

Abstract: A dosage form containing an amount of cannabidiol pressed into a tablet.

Abstract: A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed.

Abstract: Provided are antifouling particles and uses thereof in methods of anti-biofouling.

Abstract: Compositions include an extended release fat-soluble active composition. In certain aspects, the extended release fat-soluble active composition includes an extended release bead multiparticulate comprising a fat-soluble active. In other aspects, the extended release fat-soluble active composition includes an extended release lipid multiparticulate comprising a fat-soluble active.

Abstract: A combination of sheets can be combined into an ingestible unit. The individual sheets can be prepared to have one or more functionalities, such as providing a biologically active agent, disintegrating and opening the unit, controlling release of an agent, facilitating absorption from the GI tract, as well as many others. The individual sheets can be selectively identified for combining into a multifunctional ingestible unit with a random or predetermined arrangement or stacking pattern. The individual sheets can be loose in a capsule or laminated together into a stacked layered structure. The combination of sheets can be pressed, laminated, tableted, or otherwise prepared into an ingestible unit. The ingestible unit can be predetermined to be useful for administering a drug, drug combination, multi-drug regimen as well as tailored to subject-specific multi-drug therapeutic regimens. The sheets can be loaded with any type of agent ranging from drugs to anti-counterfeit agents.

Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.

Abstract: An agent, food and beverage for improving a carotenoid balance in blood by increasing the blood level of normally non-present xanthophylls while inhibiting a decrease in the blood level of normally present carotenoids is provided. It is possible to increase the blood level of normally non-present xanthophylls having high antioxidant properties while inhibiting a decrease in the blood level of normally present carotenoids, by combining: (A) at least one member selected from among capsanthin, capsorubin, capsanthone, cucurbitaxanthin A, astaxanthin, mytiloxanthin, and fatty acid esters thereof; (B) at least one member selected from among zeaxanthin, ?-cryptoxanthin, lutein, and fatty acid esters thereof; (C) at least one member selected from among ?-carotene, ?-carotene, and lycopene; and (D) at least one member selected from among vitamin E, vitamin C, and vitamin C derivatives.

Abstract: The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject.

Abstract: A method for temporarily relieving sinus congestion and pressure comprising administering to a human a dose of a multi-particle pulsatile oral dosage form with an immediate release form and a plurality of delayed release particles. The immediate release form contains about 10 mg phenylephrine hydrochloride. The delayed release form contains a core with coatings including a phenylephrine coating containing about 10 mg phenylephrine hydrochloride and a pH sensitive coating.

Abstract: Provided is a topical formulation for preventing or treating acne, including a benzenesulfonamide derivative, and a pharmaceutically or cosmetically acceptable excipient. Also provided is a method for preventing or treating acne, including applying the topical formulation on skin of a subject in need thereof.

Abstract: Disclosed herein are methods of preventing, inhibiting, reducing, or treating ischemia and reperfusion injury to tissues with glutarate compounds such as ?-ketoglutarate.

Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.

Abstract: The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.